Join Clinical Trials
  • Login
  • Home
  • Clinical Trial Categories
  • Adults - 18 - 64
  • California
  • San Diego


Menu

Choose Which Database to Search - Volunteer Database - Clinical Trial Database Create an Account - VOLUNTEER Accounts - RECRUITER Accounts Account Login - Volunteers Login - Recruiters Login Join a Clinical Trial Clinical Trials by Category Clinical Trials by Location Submit a Clinical Trial Frequently Asked Questions Contact Us Sitemap Blog

Categories

    Healthy Volunteers Adults - 18 - 64 Youths - Birth - 17 Seniors - 65 + Expanded Access Compensated Trials Clinical Trials by Condition Trials by Drug Type Trials for Rare Conditions

Recent Listings

  • Post your clinical trial on JoinClinicalTrials.com

    Ellijay, Georgia 30536
    United States

    Post your clinical trial on JoinClinicalTrials.com

    05-09-2019 01:01PM

JoinClinicalTrials.com




Results

Post your clinical trial on JoinClinicalTrials.com
Hot

Post your clinical trial on JoinClinicalTrials.com


Ellijay, Georgia 30536
United States

Post your clinical trial on JoinClinicalTrials.com to reach thousands of viewer daily. Our Clinical Trial Listings have consistently proven to be an ...

Results 1 - 1 of 1
  • <<
  • <
  • 1
  • >
  • >>

  • Modafinil Effects on EEG Biomarkers of Reward and Motivation
    NCT03616717
    Condition:   Healthy Adults
    Interventions:   Drug: Modafinil;   Drug: placebo
    Sponsor:   University of California, San Diego
    Recruiting
  • The Pride Body Project
    NCT03451513
    Conditions:   Eating Disorder;   Body Image
    Interventions:   Behavioral: Pride Body Project;   Behavioral: Media Advocacy
    Sponsors:   San Diego State University;   National Institute on Minority Health and Health Disparities (NIMHD)
    Recruiting
  • Effects of Negative Affect in Individuals With Binge Eating Episodes
    NCT03393039
    Conditions:   Bulimia Nervosa;   Binge-Eating Disorder;   Obesity;   Eating Disorder
    Intervention:   Behavioral: Negative Affect Task
    Sponsors:   University of California, San Diego;   Sanford Research;   University of Colorado, Denver
    Recruiting
  • Cognitive Training for PTSD
    NCT03316196
    Condition:   Posttraumatic Stress Disorder
    Interventions:   Behavioral: COGENT COGNITIVE TRAINING;   Behavioral: Non training computer condition
    Sponsor:   VA Office of Research and Development
    Recruiting
  • Managing MTBI-related Headaches With rTMS
    NCT03314584
    Condition:   Traumatic Brain Injury (TBI)
    Interventions:   Device: Transcranial Magnetic Stimulation;   Device: Sham Transcranial Magnetic Stimulation
    Sponsor:   VA Office of Research and Development
    Recruiting
  • Enhancement of PTSD Treatment With Computerized Executive Function Training
    NCT03260127
    Condition:   Posttraumatic Stress Disorder
    Interventions:   Behavioral: Computerized executive function training plus CPT (CEFT-CPT);   Behavioral: Word game training plus CPT (WT-CPT)
    Sponsor:   VA Office of Research and Development
    Recruiting
  • CBT-I for Veterans With TBI
    NCT02658669
    Conditions:   Insomnia;   Traumatic Brain Injury
    Interventions:   Behavioral: Cognitive-Behavioral Therapy for Insomnia;   Behavioral: Sleep Education
    Sponsor:   VA Office of Research and Development
    Recruiting
  • Perioperative Mirror Therapy and Phantom Limb Pain
    NCT02383979
    Conditions:   Phantom Limb Pain;   Phantom Pain;   Phantom Sensation;   Pseudomelia
    Interventions:   Device: Sham (Comparator) Plasma Ball;   Device: Mirror
    Sponsor:   United States Naval Medical Center, San Diego
    Recruiting
  • Phase 1, for Multiple Doses of HM15136 in Obese or Overweight Subjects With Comorbidities
    NCT04167553
    Condition:   Obese or Overweight Subjects With Comorbidities
    Interventions:   Drug: HM15136;   Drug: Placebo
    Sponsor:   Hanmi Pharmaceutical Company Limited
    Recruiting
  • A Prospective, Study Evaluating the Efficacy of DOSE Formulations in Treatment of Melasma and Cutaneous Signs of Aging
    NCT04137263
    Condition:   Melasma
    Intervention:   Other: DOSE formulation
    Sponsors:   Goldman, Butterwick, Fitzpatrick and Groff;   SkinCeuticals
    Recruiting
  • Epidermal Adhesive Sensors to Enhance Continuous Glucose Measurement in Patients With Diabetes: The EASE Study
    NCT04088201
    Condition:   Diabetes Mellitus
    Intervention:   Device: Glucose measurements
    Sponsor:   University of California, San Diego
    Recruiting
  • Evaluation of the Effects of a Rehabilitation Program in Individuals With Spine Pain
    NCT04081896
    Conditions:   Neck Pain;   Low Back Pain;   Scoliosis;   Thoracic Injuries
    Intervention:   Other: Exercise
    Sponsors:   SpineZone Medical Fitness, Inc;   University of California, San Diego
    Recruiting
  • SMILE (Small Incision Lenticule Extraction) in the DoD (Department of Defense)
    NCT04072289
    Conditions:   Myopia;   Astigmatism
    Intervention:   Device: Visumax spherocylindrical treatment
    Sponsors:   United States Naval Medical Center, San Diego;   Carl Zeiss Meditec, Inc.
    Recruiting
  • Video Education for Prenatal Testing Choices
    NCT04062968
    Condition:   Pregnancy
    Intervention:   Other: Video education
    Sponsor:   United States Naval Medical Center, San Diego
    Recruiting
  • Safety and Efficacy of Deoxycholic Acid Injection for Reduction of Upper Inner Thigh Fat
    NCT04054011
    Condition:   Adiposity
    Intervention:   Drug: Deoxycholic Acid
    Sponsor:   University of California, San Diego
    Recruiting
  • Uqora Supplements in Women With UTIs
    NCT04024046
    Condition:   Urinary Tract Infections
    Interventions:   Dietary Supplement: Uqora;   Dietary Supplement: Group1;   Dietary Supplement: Group 2
    Sponsors:   Hawthorne Effect Inc.;   Uqora, Inc.
    Recruiting
  • Transmembrane Electromyography (TM-EMG) for the Assessment of Neuromuscular Function in the Oropharynx
    NCT03986671
    Conditions:   Obstructive Sleep Apnea;   Amyotrophic Lateral Sclerosis;   Muscular Dystrophies;   Healthy
    Intervention:   Device: Transmembrane EMG Oropharynx Probe
    Sponsor:   Powell Mansfield Inc.
    Recruiting
  • Compassion Meditation for Older Adults
    NCT03964246
    Condition:   Anxiety and Mood Disorders
    Interventions:   Behavioral: Compassion Meditation (CM) intervention;   Other: Heathy Aging Psychoeducation
    Sponsor:   VA Office of Research and Development
    Recruiting
  • Vagal Nerve Stimulation to Probe Inflammation and Brain in Post-traumatic Stress
    NCT03858985
    Condition:   Post-traumatic Stress
    Interventions:   Device: Cervical Transcutaneous Vagus Nerve Stimulation (Active Comparator);   Device: Cervical Transcutaneous Vagus Nerve Stimulation (Sham Comparator)
    Sponsor:   VA Office of Research and Development
    Recruiting
  • Evaluation of an Incentive-based Intervention to Improve 90-day Adherence in PAP-Naive Patients
    NCT03851094
    Condition:   Obstructive Sleep Apnea
    Intervention:   Behavioral: Wellth app
    Sponsors:   ResMed;   Wellth Inc.
    Recruiting
  • Efficacy and Safety of Orally Administered DS107 in Adult Patients With Moderate to Severe Atopic Dermatitis
    NCT03817190
    Condition:   Atopic Dermatitis
    Interventions:   Drug: DS107;   Drug: Placebo
    Sponsor:   DS Biopharma
    Recruiting
  • Biomarker Predictors of Memantine Sensitivity in Patients With Alzheimer's Disease
    NCT03703856
    Condition:   Alzheimer Disease
    Interventions:   Drug: Memantine;   Drug: Placebo
    Sponsor:   University of California, San Diego
    Recruiting
  • Acceptance and Commitment Therapy for Aging People Living With HIV in Chronic Pain
    NCT03699020
    Conditions:   HIV/AIDS;   Chronic Pain
    Interventions:   Behavioral: Acceptance and Commitment Therapy (ACT);   Other: Chronic Pain Education
    Sponsors:   University of California, San Diego;   National Institute on Aging (NIA)
    Recruiting
  • Alzheimer Prevention Trials (APT) Webstudy
    NCT03638583
    Conditions:   Alzheimer Disease;   Dementia
    Intervention:  
    Sponsors:   University of Southern California;   National Institute on Aging (NIA);   Brigham and Women's Hospital;   The Cleveland Clinic
    Recruiting
  • Obstructive Sleep Apnea Endotypes and Impact on Phenotypes of People Living With HIV
    NCT03575143
    Conditions:   Human Immunodeficiency Virus;   Obstructive Sleep Apnea
    Intervention:  
    Sponsor:   University of California, San Diego
    Recruiting
  • Personalized Immunotherapy in Adults With Advanced Cancers Immunotherapy in Adults With Advanced Cancers
    NCT03568058
    Condition:   Advanced Cancer
    Interventions:   Drug: personalized vaccine;   Drug: Pembrolizumab
    Sponsor:   Ezra Cohen
    Recruiting
  • Low-dose CT-based Method for Detection of Subclinical Anthracycline-induced Cardiotoxicity
    NCT03553654
    Condition:   Neoplasms
    Intervention:   Diagnostic Test: low dose CT
    Sponsor:   University of California, San Diego
    Recruiting
  • Impact of DAA Uptake in Controlling HCV Epidemic and Modeling Interventions for HCV Elimination Among HIV-infected Persons in San Diego
    NCT03551002
    Conditions:   Hepatitis C;   Hepatitis C, Chronic;   HIV/AIDS
    Intervention:  
    Sponsor:   University of California, San Diego
    Recruiting
  • Self-Management of Continuous Positive Airway Pressure Settings
    NCT03536572
    Condition:   Obstructive Sleep Apnea
    Intervention:   Behavioral: Sleep Apnea Self-Management Program
    Sponsor:   VA Office of Research and Development
    Recruiting
  • Cannabidiol and Prolonged Exposure
    NCT03518801
    Condition:   PTSD
    Interventions:   Behavioral: Prolonged Exposure;   Drug: Cannabidiol;   Drug: placebo
    Sponsors:   VA Office of Research and Development;   University of California, San Diego
    Recruiting
  • Yoga and Physical Activity for Veterans
    NCT03509909
    Condition:   PTSD
    Interventions:   Behavioral: Hatha yoga;   Behavioral: Supportive physical activity
    Sponsor:   VA Office of Research and Development
    Recruiting
  • Physical Therapy for Anal Incontinence
    NCT03252951
    Conditions:   Anal Incontinence;   Fecal Incontinence
    Interventions:   Behavioral: Eccentric Training;   Behavioral: Concentric Training;   Behavioral: Isometric Training;   Behavioral: Biofeedback
    Sponsors:   San Diego State University;   University of California, San Diego
    Recruiting
  • A Prospective Trial of Behavioral Therapy for Chronic Cough
    NCT03235466
    Condition:   Cough
    Interventions:   Behavioral: Voice Therapy;   Behavioral: Voice Therapy and Heart Rate Variability Biofeedback;   Behavioral: Heart Rate Variability Biofeedback
    Sponsor:   University of California, San Diego
    Recruiting
  • Topiramate and Prolonged Exposure
    NCT03176953
    Condition:   PTSD and Alcohol Use Disorder
    Interventions:   Drug: topiramate;   Behavioral: prolonged exposure;   Drug: placebo
    Sponsors:   VA Office of Research and Development;   University of California, San Diego
    Recruiting
  • The Pathogenesis of OSA in People Living With HIV
    NCT03064204
    Conditions:   Obstructive Sleep Apnea;   HIV/AIDS
    Intervention:  
    Sponsors:   University of California, San Diego;   Center For AIDS Research Creative and Novel Ideas in HIV Research (CFAR CNIHR)
    Recruiting
  • Integrated CBT-I and PE on Sleep and PTSD Outcomes (Impact Study)
    NCT02774642
    Conditions:   Posttraumatic Stress Disorders;   Chronic Insomnia
    Interventions:   Behavioral: CBTI-PE;   Behavioral: Hygiene-PE
    Sponsor:   VA Office of Research and Development
    Recruiting
  • Cognitive-Behavioral Conjoint Therapy (CBCT) Project
    NCT02720016
    Condition:   Post Traumatic Stress Disorder
    Interventions:   Behavioral: CBCT-Home Based (CBCT-HB);   Behavioral: CBCT-Office Based (CBCT-OB);   Behavioral: PTSD Family Education (PFE)
    Sponsor:   VA Office of Research and Development
    Recruiting
  • Perturbing of HIV Reservoir With Immune Stimulation
    NCT02707692
    Conditions:   AIDS;   HIV
    Interventions:   Biological: Fluarix;   Biological: Pneumovax;   Other: Placebo
    Sponsors:   University of California, San Diego;   National Institute of Allergy and Infectious Diseases (NIAID)
    Recruiting
  • OTIS Vedolizumab Pregnancy Exposure Registry
    NCT02678052
    Conditions:   Colitis, Ulcerative;   Crohn's Disease
    Interventions:   Drug: Vedolizumab;   Biological: Other Biological Agent
    Sponsor:   Takeda
    Recruiting
  • Impact of Hepatitis C Virus Therapy on Central Nervous System Outcomes
    NCT02650024
    Conditions:   Hepatitis C;   Human Immunodeficiency Virus
    Intervention:  
    Sponsor:   University of California, San Diego
    Recruiting
  • Efficacy of ART to Interrupt HIV Transmission Networks
    NCT02528773
    Condition:   HIV
    Intervention:  
    Sponsor:   University of California, San Diego
    Recruiting
  • Cognitive Rehab and Exposure Treatment for Hoarding
    NCT02402647
    Condition:   Hoarding Disorder
    Interventions:   Behavioral: CREST;   Behavioral: ET
    Sponsor:   VA Office of Research and Development
    Recruiting
  • Effects of Watermelon Consumption on Satiety and Digestive Health
    NCT04096586
    Condition:   Satiety
    Interventions:   Other: Red juice;   Other: Watermelon juice
    Sponsor:   San Diego State University
    Recruiting
  • Transoral Daytime Neuromuscular Electrical Stimulation in Patients With Simple Snoring
    NCT03913494
    Conditions:   Sleep Apnea, Obstructive;   Sleep Apnea;   Sleep;   Snoring
    Intervention:   Device: Transoral Neurostimulation Device (Snoozeal)
    Sponsor:   University of California, San Diego
    Recruiting
  • Sleep Disordered Breathing in Acute Congestive Heart Failure
    NCT03804827
    Conditions:   Obstructive Sleep Apnea;   Heart Failure; With Decompensation
    Intervention:  
    Sponsor:   University of California, San Diego
    Recruiting
  • Digital Health Feedback System (DHFS) for Longitudinal Monitoring of ARVs Used in HIV Pre-exposure Prophylaxis (PrEP)
    NCT03693040
    Condition:   HIV Prevention
    Intervention:   Device: Digital Health Feedback System
    Sponsors:   University of California, San Diego;   National Institute of Mental Health (NIMH);   Gilead Sciences;   Proteus Digital Health, Inc.
    Recruiting
  • Cabozantinib in Combination With 13-cis-Retinoic Acid in Children With Relapsed or Refractory Solid Tumors
    NCT03611595
    Condition:   Solid Tumor
    Interventions:   Drug: Cabozantinib;   Drug: 13-cis-retinoic acid
    Sponsors:   Peter Zage;   Exelixis
    Recruiting
  • Digital Health Feedback System for Longitudinal Measurement of Medication Adherence During Anti-Retroviral (ARV)Therapy
    NCT02800655
    Condition:   HIV
    Intervention:   Device: Digital Health Feedback System
    Sponsors:   University of California, San Diego;   National Institute of Mental Health (NIMH);   Gilead Sciences;   ViiV Healthcare;   GlaxoSmithKline;   Proteus Digital Health, Inc.
    Recruiting
  • Improving Office Based Treatment of Opioid Use Disorder With Technology
    NCT03586466
    Condition:   Opioid-use Disorder
    Interventions:   Device: BupreCare;   Drug: Buprenorphine/naloxone;   Other: MEMS
    Sponsors:   MedicaSafe, Inc.;   Friends Research Institute, Inc.
    Recruiting
  • Evaluating the Use of Peer Specialists to Deliver Cognitive Behavioral Social Skills Training
    NCT03467243
    Condition:   Serious Mental Illness
    Interventions:   Behavioral: Cognitive Behavioral Social Skills Training;   Behavioral: Social Skills Training;   Behavioral: Treatment as usual
    Sponsor:   VA Office of Research and Development
    Recruiting
  • Cognitive Rehabilitation Therapy for Mild Cognitive Impairment
    NCT03225482
    Condition:   Mild Cognitive Impairment
    Interventions:   Behavioral: Motivationally Enhanced Compensatory Cognitive Training;   Behavioral: Goal-focused Supportive Contact
    Sponsors:   VA Office of Research and Development;   Portland VA Medical Center
    Recruiting
  • Self-management of Blood Pressure Medication for Hypertensive Veterans
    NCT03224624
    Condition:   Hypertension
    Intervention:   Other: self-management protocol for hypertension care
    Sponsor:   VA Office of Research and Development
    Recruiting
  • Text Messaging to Engage and Retain Veterans in Smoking Cessation Counseling
    NCT03177265
    Condition:   Nicotine Dependence
    Interventions:   Behavioral: Text messaging prior to first counseling call;   Behavioral: Text-to-Enhance;   Behavioral: Mail Notice;   Behavioral: Telephone Counseling
    Sponsor:   VA Office of Research and Development
    Recruiting
  • Evaluation of Conventional Ablation With or Without Focal Impulse and Rotor Modulation to Eliminate Human AF
    NCT02456233
    Condition:   Atrial Fibrillation
    Interventions:   Procedure: Conventional AF Ablation with PVI;   Procedure: FIRM-guided ablation plus PVI
    Sponsor:   Stanford University
    Recruiting
  • Chronic Low Back Pain and Meditation
    NCT04034004
    Condition:   Pain
    Interventions:   Behavioral: Mindfulness;   Drug: Naloxone;   Other: Saline;   Behavioral: Meditation
    Sponsor:   University of California, San Diego
    Recruiting
  • Directed Use of REmote Patient Management System AMia to Achieve Prescribed Dry Weight
    NCT04002440
    Conditions:   Efficacy;   Safety Issues
    Interventions:   Combination Product: AMIA with SHARESOURCE Connectivity Platform;   Device: HomeChoice PRO
    Sponsors:   University of California, San Diego;   Baxter Healthcare Corporation;   Scripps Health;   Home Dialysis Therapies of San Diego
    Recruiting
  • HTX-011 Administration Study in Planned Caesarean Section Procedure
    NCT03955211
    Condition:   Analgesia
    Interventions:   Drug: HTX-011;   Device: Luer lock applicator
    Sponsor:   Heron Therapeutics
    Recruiting
  • Paracervical Block Volume and Pain Control During Dilation and Curettage
    NCT03636451
    Conditions:   Abortion, Spontaneous;   Abortion in First Trimester;   Pain Uterus
    Interventions:   Drug: 0.5% Lidocaine;   Drug: 1% Lidocaine
    Sponsors:   University of California, San Diego;   Society of Family Planning
    Recruiting
  • Connecting Women to Care: Home-based Psychotherapy for Women With MST Living in Rural Areas
    NCT03429166
    Condition:   PTSD
    Interventions:   Behavioral: STAIR;   Behavioral: PCT
    Sponsors:   VA Office of Research and Development;   San Diego Veterans Healthcare System
    Recruiting
  • Trial to Reduce Sitting Time in Postmenopausal Latina Women at Increased Risk for Heart Disease
    NCT02905929
    Condition:   Sedentary Lifestyle
    Interventions:   Device: ActivPAL inclinometer;   Behavioral: Phone counseling call: Breaking up sitting time;   Behavioral: In-person counseling: Breaking up sitting time;   Behavioral: Phone counseling call: Healthy living;   Other: Tools to prompt standing;   Behavioral: In-person counseling: Healthy living
    Sponsors:   University of California, San Diego;   South Bay Latino Research Center;   San Ysidro Health Center;   San Diego State University
    Recruiting
  • Safety Study for Prospective Assessment of Pregnancy Outcomes in Patients Treated With Tildrakizumab
    NCT03992729
    Condition:   Pregnancy Related
    Interventions:   Drug: Pregnant women exposed to tildrakizumab;   Drug: Pregnant women not exposed to tildrakizumab
    Sponsor:   Sun Pharma Global FZE
    Recruiting
  • Characteristics and Inflammatory Markers in Children With Eosinophilic Esophagitis (EoE)
    NCT03980886
    Condition:   Eosinophilic Esophagitis
    Intervention:  
    Sponsors:   University of California, San Diego;   National Institutes of Health (NIH);   National Institute of Allergy and Infectious Diseases (NIAID)
    Recruiting
  • Mindful Action for Pain
    NCT03800654
    Condition:   Chronic Pain
    Interventions:   Behavioral: Mindful Action for Pain;   Behavioral: Cognitive Behavioral Therapy for Chronic Pain
    Sponsor:   VA Office of Research and Development
    Recruiting
  • Benralizumab Pregnancy Exposure Study
    NCT03794999
    Condition:   Asthma
    Interventions:   Drug: Benralizumab-exposure;   Drug: Exposure to other asthma medications
    Sponsors:   AstraZeneca;   University of California, San Diego, Department of Pediatrics
    Recruiting
  • Antibiotic Prophylaxis With Routine Ureteral Stent Removal
    NCT02944825
    Conditions:   Urolithiasis;   UTI
    Interventions:   Drug: Ciprofloxacin;   Drug: trimethoprim/sulfamethoxazole;   Drug: No Intervention
    Sponsors:   University of California, San Diego;   Genesis HealthCare
    Recruiting
  • Endourology Disease Group Excellence (EDGE) Consortium: Antibiotics (Abx) for Percutaneous Nephrolithotomy (PCNL) Part 2
    NCT02829060
    Conditions:   Nephrolithiasis;   Urinary Tract Infection (UTI);   Sepsis
    Interventions:   Drug: Nitrofurantoin 100 MG, 7d;   Drug: Gentamicin, 5mg/kg;   Drug: Ampicillin 2g;   Drug: Nitrofurantoin 100 mg, 48 hrs;   Drug: Gentamicin, 80 mg, 7d;   Drug: Gentamicin, 80 mg, 48hr
    Sponsor:   University of California, San Diego
    Recruiting
  • VDOT for Monitoring Adherence to LTBI Treatment
    NCT02641106
    Conditions:   Tuberculosis;   Latent Tuberculosis Infection
    Interventions:   Other: Video Directly Observed Therapy;   Other: In-Person DOT
    Sponsor:   University of California, San Diego
    Recruiting
  • OTIS Autoimmune Diseases in Pregnancy Project
    NCT01797224
    Conditions:   Crohn's Disease;   Rheumatoid Arthritis;   Ankylosing Spondylitis;   Psoriatic Arthritis;   Psoriasis
    Intervention:  
    Sponsors:   University of California, San Diego;   The Organization of Teratology Information Specialists;   UCB Pharma
    Recruiting
  • Long-term, Non-interventional, Observational Study Following Treatment With Fate Therapeutics FT500 Cellular Immunotherapy
    NCT04106167
    Conditions:   Advanced Solid Tumor;   Lymphoma;   Gastric Cancer;   Colorectal Cancer;   Head and Neck Cancer;   Squamous Cell Carcinoma;   EGFR Positive Solid Tumor;   HER2-positive Breast Cancer;   Hepatocellular Carcinoma;   Small-cell Lung Cancer;   Renal Cell Carcinoma;   Pancreas Cancer;   Melanoma;   NSCLC;   Urothelial Carcinoma;   Cervical Cancer;   Microsatellite Instability;   Merkel Cell Carcinoma
    Intervention:   Genetic: Allogeneic natural killer (NK) cell
    Sponsor:   Fate Therapeutics
    Recruiting
  • Phase I Trial HIPEC With Nal-irinotecan
    NCT04088786
    Conditions:   Peritoneal Cancer;   Pseudomyxoma Peritonei;   Mucinous Adenocarcinoma;   Mucinous Tumor;   Colorectal Cancer;   Gastric Cancer;   Primary Peritoneal Carcinoma;   Mesothelioma
    Intervention:   Drug: nanoliposomal irinotecan
    Sponsors:   Stony Brook University;   University of Kentucky;   University of San Diego
    Recruiting
  • Telehealth Intervention for Improved Blood Pressure Control With Targeted Incentives
    NCT04075045
    Conditions:   Hypertension;   Non-Adherence, Patient
    Interventions:   Behavioral: Wellth Smartphone App;   Behavioral: Targeted Incentives;   Behavioral: Non-Restricted Incentives
    Sponsors:   Wellth Inc.;   University of California, San Diego
    Recruiting
  • FT500 as Monotherapy and in Combination With Immune Checkpoint Inhibitors in Subjects With Advanced Solid Tumors
    NCT03841110
    Conditions:   Advanced Solid Tumors;   Lymphoma;   Gastric Cancer;   Colorectal Cancer;   Head and Neck Cancer;   Squamous Cell Carcinoma;   EGFR Positive Solid Tumor;   HER2-positive Breast Cancer;   Hepatocellular Carcinoma;   Small Cell Lung Cancer;   Renal Cell Carcinoma;   Pancreas Cancer;   Melanoma;   NSCLC;   Urothelial Carcinoma;   Cervical Cancer;   Microsatellite Instability;   Merkel Cell Carcinoma
    Interventions:   Drug: FT500;   Drug: Nivolumab;   Drug: Pembrolizumab;   Drug: Atezolizumab;   Drug: Cyclophosphamide;   Drug: Fludarabine
    Sponsor:   Fate Therapeutics
    Recruiting
  • Pharmacokinetics of IFX and TNF Concentrations in Serum, Stool, and Colonic Mucosa in Acute Severe Ulcerative Colitis
    NCT03765450
    Condition:   Ulcerative Colitis
    Intervention:   Drug: Infliximab
    Sponsor:   Robarts Clinical Trials Inc.
    Recruiting
  • Remote Sleep Apnea Management
    NCT03007745
    Conditions:   Sleep Apnea - Obstructive;   Cost Effectiveness;   Telemedicine
    Intervention:   Device: autoadjusting continuous positive airway pressure
    Sponsor:   VA Office of Research and Development
    Recruiting
  • Collaborative Care for Women Veterans
    NCT02950961
    Conditions:   Anxiety;   Depression;   Stress Disorders, Post Traumatic
    Intervention:   Behavioral: Collaborative Care for Women Veterans
    Sponsor:   VA Office of Research and Development
    Recruiting
  • Long Term Efficacy of Neuronavigation Guided rTMS in Alleviating Gulf War Illness Related Headaches and Pain Symptoms
    NCT04182659
    Conditions:   Gulf War Syndrome;   Gulf War Illness;   Headache;   Muscle Pain;   Joint Pain
    Interventions:   Device: Transcranial Magnetic Stimulation;   Device: Sham Transcranial Magnetic Stimulation
    Sponsors:   Veterans Medical Research Foundation;   United States Department of Defense
    Recruiting
  • Clinical Evaluation of the Connected Catheter - Wireless Urinary Prosthesis for Management of Chronic Urinary Retention
    NCT04059159
    Conditions:   Neurogenic Bladder;   Urinary Retention;   Urologic Diseases
    Intervention:   Device: Connected Catheter
    Sponsors:   Spinal Singularity;   National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
    Recruiting
  • rTMS in Alleviating Pain and Co-Morbid Symptoms in Gulf War Veterans Illness (GWVI)
    NCT04046536
    Conditions:   Gulf War Illness;   Depression
    Interventions:   Device: Transcranial Magnetic Stimulation;   Device: Sham Transcranial Magnetic Stimulation
    Sponsor:   VA Office of Research and Development
    Recruiting
  • Early vs. Interval Postpartum IUD Insertion
    NCT03462758
    Condition:   Contraception
    Intervention:   Device: IUD
    Sponsors:   University of California, San Diego;   University of New Mexico;   United States Naval Medical Center, San Diego
    Recruiting
  • Study for the Prediction of Active Rejection in Organs Using Donor-derived Cell-free DNA Detection
    NCT03984747
    Conditions:   Kidney Transplant Rejection;   Allograft Rejection;   Kidney Transplant; Complications
    Intervention:  
    Sponsor:   Natera, Inc.
    Recruiting
  • Carfilzomib With Bendamustine and Rituximab in Patients With Relapsed or Refractory Non-Hodgkin Lymphoma
    NCT02187133
    Conditions:   Lymphoma, Non-Hodgkin;   Lymphoma
    Interventions:   Drug: Carfilzomib;   Drug: Bendamustine;   Drug: Rituximab
    Sponsors:   University of California, San Francisco;   National Comprehensive Cancer Network
    Recruiting
  • Comprehensive Computed Tomography Guidance of Coronary Bypass Graft Surgery
    NCT03894423
    Conditions:   CAD;   Atheroscleroses, Coronary;   Computed Tomography;   Coronary Artery Bypass
    Intervention:  
    Sponsors:   Stanford University;   National Heart, Lung, and Blood Institute (NHLBI);   University of California, San Diego;   VA Palo Alto Health Care System
    Recruiting
  • A Healthy Relationships Program for Vulnerable Youth
    NCT03736876
    Conditions:   Pregnancy, Unplanned;   Sexually Transmitted Diseases
    Intervention:   Behavioral: About Us
    Sponsors:   ETR Associates;   Family and Youth Services Bureau;   San Diego State University;   California School-Based Health Alliance
    Recruiting
  • A Real World, Multicenter, Open-Label Study to Assess the Effectiveness of, and Satisfaction With, CCH Treatment of Cellulite in Adult Females
    NCT04170296
    Conditions:   Edematous Fibrosclerotic Panniculopathy (EFP);   Cellulite
    Intervention:   Drug: EN3835
    Sponsor:   Endo Pharmaceuticals
    Recruiting
  • Short-course Benznidazole Treatment to Reduce Trypanosoma Cruzi Parasitic Load in Women of Reproductive Age
    NCT03672487
    Condition:   Chagas Disease
    Interventions:   Drug: Benznidazole;   Drug: Placebo Oral Tablet
    Sponsors:   Tulane University School of Public Health and Tropical Medicine;   Institute for Clinical Effectiveness and Health Policy;   University of California, San Diego
    Recruiting
  • Glecaprevir/Pibrentasvir Fixed-dose Combination Treatment for Acute Hepatitis C Virus Infection
    NCT04042740
    Conditions:   Hepatitis C Infection;   HIV Infection
    Interventions:   Drug: Glecaprevir/Pibrentasvir (G/P);   Drug: Ribavirin (RBV)
    Sponsors:   AIDS Clinical Trials Group;   AbbVie;   National Institute of Allergy and Infectious Diseases (NIAID)
    Recruiting
  • FATE-NK100 as Monotherapy and in Combination With Monoclonal Antibody in Subjects With Advanced Solid Tumors
    NCT03319459
    Conditions:   HER2 Positive Gastric Cancer;   Colorectal Cancer;   Head and Neck Squamous Cell Carcinoma;   EGFR Positive Solid Tumor;   Advanced Solid Tumors;   HER2-positive Breast Cancer;   Hepatocellular Carcinoma;   Non Small Cell Lung Cancer;   Renal Cell Carcinoma;   Pancreatic Cancer;   Melanoma
    Interventions:   Drug: FATE-NK100;   Drug: Cetuximab;   Drug: Trastuzumab
    Sponsor:   Fate Therapeutics
    Recruiting
  • Psychosocial Rehabilitation After Moral Injury and Loss With Adaptive Disclosure
    NCT03056157
    Conditions:   Post-traumatic Stress Disorder;   Moral Injury;   Traumatic Loss
    Interventions:   Behavioral: Adaptive Disclosure for Moral Injury and Loss;   Behavioral: Present Centered Therapy
    Sponsors:   VA Office of Research and Development;   Minneapolis Veterans Affairs Medical Center;   San Francisco Veterans Affairs Medical Center;   San Diego Veterans Healthcare System
    Recruiting
  • A Phase 3 Trial of Brexpiprazole as Combination Therapy With Sertraline in Treatment of Adults With PTSD
    NCT04124614
    Condition:   Post Traumatic Stress Disorder
    Interventions:   Drug: Brexpiprazole;   Drug: Sertraline;   Other: Placebo
    Sponsor:   Otsuka Pharmaceutical Development & Commercialization, Inc.
    Recruiting
  • Safety and Tolerability of PNT001 in Healthy Adults
    NCT04096287
    Condition:   Healthy
    Interventions:   Biological: PNT001;   Drug: Placebo
    Sponsor:   Pinteon Therapeutics, Inc
    Recruiting
  • Study of Personalized Cancer Therapy to Determine Response and Toxicity
    NCT02478931
    Condition:   Cancer
    Intervention:  
    Sponsor:   Razelle Kurzrock, MD
    Recruiting
  • A Pilot Evaluation of BLI4900 Bowel Preparation in Adult Subjects
    NCT03328507
    Condition:   Colonoscopy
    Interventions:   Drug: BLI4900;   Drug: PEG Control
    Sponsor:   Braintree Laboratories
    Recruiting
  • Mature B-Cell Lymphoma And Leukemia Study III
    NCT01046825
    Condition:   Mature B-Cell Lymphoma
    Interventions:   Drug: COPAD;   Drug: COP, COPD M3, CYM;   Drug: COP, COPADM8, CYVE
    Sponsor:   St. Jude Children's Research Hospital
    Recruiting
  • Safety and Efficacy Study of MT-2990 in Women With Endometriosis
    NCT03840993
    Condition:   Endometrial Related Pain
    Interventions:   Drug: MT-2990;   Drug: Placebo
    Sponsor:   Mitsubishi Tanabe Pharma Development America, Inc.
    Recruiting
  • Study of the Safety and Efficacy of Elagolix in Women With Polycystic Ovary Syndrome
    NCT03951077
    Condition:   Polycystic Ovary Syndrome
    Interventions:   Drug: Elagolix;   Drug: Placebo
    Sponsor:   AbbVie
    Recruiting
  • A Study to Evaluate the Safety and Efficacy of Elagolix for the Management of Heavy Menstrual Bleeding Associated With Uterine Fibroids in Premenopausal Women
    NCT03886220
    Condition:   Uterine Fibroids
    Interventions:   Drug: Elagolix;   Drug: Placebo
    Sponsor:   AbbVie
    Recruiting
  • A Study to Evaluate the Safety and Efficacy of BIIB104 in Participants With Cognitive Impairment Associated With Schizophrenia (CIAS)
    NCT03745820
    Conditions:   Cognitive Impairment Associated With Schizophrenia;   Schizophrenia
    Interventions:   Drug: BIIB104;   Other: Placebo
    Sponsor:   Biogen
    Recruiting
  • Clinical Trial Evaluating the Efficacy, Safety, and Tolerability of Cariprazine in a Dose-Reduction Paradigm in the Prevention of Relapse in Patients With Schizophrenia
    NCT03593213
    Condition:   Schizophrenia
    Interventions:   Drug: Cariprazine;   Drug: Placebo
    Sponsor:   Forest Laboratories
    Recruiting
  • Effects of Emicizumab vs. Factor VIII Prophylaxis on Joint and Bone Health in Severe Hemophilia A
    NCT04131036
    Condition:   Hemophilia A
    Intervention:   Other: assessment of joint health and bone density
    Sponsors:   Bloodworks;   Genentech, Inc.
    Recruiting
  • SPIRIT 1: Efficacy and Safety Study of Relugolix in Women With Endometriosis-Associated Pain
    NCT03204318
    Condition:   Endometriosis Related Pain
    Interventions:   Drug: Relugolix;   Drug: Estradiol/norethindrone acetate;   Drug: Placebo for E2/NETA;   Drug: Placebo for relugolix
    Sponsor:   Myovant Sciences GmbH
    Recruiting
  • Work Ability in Young Adult Cancer Survivors
    NCT03148080
    Condition:   Cancer Survivor
    Interventions:   Procedure: Cognitive Assessment;   Other: Questionnaire Administration
    Sponsors:   Wake Forest University Health Sciences;   National Cancer Institute (NCI)
    Recruiting
  • BEACH Trial: Bovine Early Access, Compatibility and Hemostasis Trial
    NCT04146012
    Condition:   Renal Insufficiency,Chronic
    Intervention:   Device: Artegraft® Collagen Vascular Graft™ (Artegraft)
    Sponsor:   Artegraft, Inc.
    Recruiting
  • Ibrutinib and Brentuximab Vedotin in Treating Patients With Relapsed or Refractory Hodgkin Lymphoma
    NCT02744612
    Conditions:   Recurrent Hodgkin Lymphoma;   Refractory Hodgkin Lymphoma
    Interventions:   Drug: Brentuximab Vedotin;   Drug: Ibrutinib
    Sponsors:   City of Hope Medical Center;   National Cancer Institute (NCI)
    Recruiting
  • AMG0103 in Subjects With Chronic Discogenic Lumbar Back Pain
    NCT03263611
    Condition:   Degenerative Disc Disease
    Interventions:   Drug: Placebo;   Drug: AMG0103
    Sponsor:   AnGes, Inc.
    Recruiting
  • Phase II Protocol of Proton Therapy for Partial Breast Irradiation in Early Stage Breast Cancer
    NCT01766297
    Conditions:   Breast Cancer;   Breast Neoplasm;   Breast Tumor;   Cancer of the Breast
    Intervention:   Radiation: Proton Radiotherapy
    Sponsor:   Proton Collaborative Group
    Recruiting
  • A Study to Assess PV-10 Chemoablation of Cancer of the Liver
    NCT00986661
    Conditions:   Cancer Metastatic to the Liver;   Hepatocellular Carcinoma;   Metastatic Melanoma;   Metastatic Ocular Melanoma;   Metastatic Uveal Melanoma;   Metastatic Lung Cancer;   Metastatic Colon Cancer;   Metastatic Colorectal Cancer;   Metastatic Breast Cancer;   Metastatic Pancreatic Cancer
    Intervention:   Drug: PV-10 (10% rose bengal disodium)
    Sponsor:   Provectus Biopharmaceuticals, Inc.
    Recruiting
  • Hypo-fractionated Radiation Therapy With or Without Androgen Suppression for Intermediate Risk Prostate Cancer
    NCT01492972
    Condition:   Prostate Cancer
    Interventions:   Radiation: Radiation;   Drug: Androgen Suppression Therapy
    Sponsor:   Proton Collaborative Group
    Recruiting
  • CPX-351 and Gemtuzumab Ozogamicin in Treating Patients With Relapsed Acute Myeloid Leukemia
    NCT03904251
    Condition:   Acute Myelogenous Leukemia
    Interventions:   Drug: Gemtuzumab Ozogamicin;   Drug: Liposome-encapsulated Daunorubicin-Cytarabine
    Sponsors:   Jonsson Comprehensive Cancer Center;   National Cancer Institute (NCI)
    Recruiting
  • Ibrutinib and Azacitidine for Treatment of Higher Risk Myelodysplastic Syndrome
    NCT02553941
    Conditions:   Chronic Myelomonocytic Leukemia;   de Novo Myelodysplastic Syndrome;   Previously Treated Myelodysplastic Syndrome;   Refractory Anemia With Excess Blasts in Transformation;   Secondary Myelodysplastic Syndrome
    Interventions:   Drug: Azacitidine;   Drug: Ibrutinib
    Sponsors:   Brian Jonas;   Pharmacyclics LLC.
    Recruiting
  • A Study to Evaluate the Effect of Testosterone Replacement Therapy (TRT) on the Incidence of Major Adverse Cardiovascular Events (MACE) and Efficacy Measures in Hypogonadal Men
    NCT03518034
    Conditions:   Hypogonadism;   Cardiovascular Diseases
    Interventions:   Drug: Testosterone;   Drug: Placebo
    Sponsors:   AbbVie;   Acerus Pharmaceuticals Corporation;   Allergan Sales, LLC;   Endo Pharmaceuticals;   Upsher-Smith Laboratories
    Recruiting
  • Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)
    NCT02465060
    Conditions:   Advanced Malignant Solid Neoplasm;   Bladder Carcinoma;   Breast Carcinoma;   Cervical Carcinoma;   Colon Carcinoma;   Colorectal Carcinoma;   Endometrial Carcinoma;   Esophageal Carcinoma;   Gastric Carcinoma;   Glioma;   Head and Neck Carcinoma;   Kidney Carcinoma;   Liver and Intrahepatic Bile Duct Carcinoma;   Lung Carcinoma;   Lymphoma;   Malignant Uterine Neoplasm;   Melanoma;   Ovarian Carcinoma;   Pancreatic Carcinoma;   Plasma Cell Myeloma;   Prostate Carcinoma;   Rectal Carcinoma;   Recurrent Bladder Carcinoma;   Recurrent Breast Carcinoma;   Recurrent Cervical Carcinoma;   Recurrent Colon Carcinoma;   Recurrent Colorectal Carcinoma;   Recurrent Esophageal Carcinoma;   Recurrent Gastric Carcinoma;   Recurrent Glioma;   Recurrent Head and Neck Carcinoma;   Recurrent Liver Carcinoma;   Recurrent Lung Carcinoma;   Recurrent Lymphoma;   Recurrent Malignant Solid Neoplasm;   Recurrent Melanoma;   Recurrent Ovarian Carcinoma;   Recurrent Pancreatic Carcinoma;   Recurrent Plasma Cell Myeloma;   Recurrent Prostate Carcinoma;   Recurrent Rectal Carcinoma;   Recurrent Skin Carcinoma;   Recurrent Thyroid Gland Carcinoma;   Recurrent Uterine Corpus Carcinoma;   Refractory Lymphoma;   Refractory Malignant Solid Neoplasm;   Refractory Plasma Cell Myeloma;   Skin Carcinoma;   Thyroid Gland Carcinoma;   Uterine Corpus Cancer
    Interventions:   Drug: Adavosertib;   Drug: Afatinib;   Drug: Afatinib Dimaleate;   Drug: Binimetinib;   Drug: Capivasertib;   Drug: Copanlisib;   Drug: Copanlisib Hydrochloride;   Drug: Crizotinib;   Other: Cytology Specimen Collection Procedure;   Drug: Dabrafenib;   Drug: Dabrafenib Mesylate;   Drug: Dasatinib;   Drug: Defactinib;   Drug: Defactinib Hydrochloride;   Drug: Erdafitinib;   Drug: FGFR Inhibitor AZD4547;   Drug: Ipatasertib;   Other: Laboratory Biomarker Analysis;   Drug: Larotrectinib;   Drug: Larotrectinib Sulfate;   Biological: Nivolumab;   Drug: Osimertinib;   Drug: Palbociclib;   Biological: Pertuzumab;   Drug: PI3K-beta Inhibitor GSK2636771;   Drug: Sapanisertib;   Drug: Sunitinib Malate;   Drug: Taselisib;   Drug: Trametinib;   Biological: Trastuzumab;   Biological: Trastuzumab Emtansine;   Drug: Ulixertinib;   Drug: Vismodegib
    Sponsor:   National Cancer Institute (NCI)
    Recruiting
  • Study for Participants With Ulcerative Colitis Previously Enrolled in Etrolizumab Phase II/III Studies
    NCT02118584
    Condition:   Ulcerative Colitis
    Intervention:   Drug: Etrolizumab
    Sponsor:   Hoffmann-La Roche
    Recruiting
  • A Study of Talazoparib in Men With DNA Repair Defects and Metastatic Castration-Resistant Prostate Cancer
    NCT03148795
    Condition:   Prostate Cancer
    Intervention:   Drug: Talazoparib
    Sponsors:   Pfizer;   Medivation, Inc.
    Recruiting
  • Breast Cancer WEight Loss Study (BWEL Study)
    NCT02750826
    Condition:   Breast Carcinoma
    Interventions:   Other: Health Education Program;   Other: Weight Loss Intervention
    Sponsors:   Alliance for Clinical Trials in Oncology;   National Cancer Institute (NCI);   Division of Cancer Control;   NIH Biomarker, Imaging and Quality of Life Studies Funding Program (BIQSFP);   Canadian Cancer Trials Group
    Recruiting
  • Long-Term Safety Study Of Tofacinib In Patients With Juvenile Idiopathic Arthritis
    NCT01500551
    Condition:   Juvenile Idiopathic Arthritis
    Intervention:   Drug: Tofacitinib
    Sponsor:   Pfizer
    Recruiting
  • A Study to Find Out How Safe Long-term Treatment With Fezolinetant is in Women With Hot Flashes Going Through Menopause
    NCT04003389
    Condition:   Hot Flashes
    Interventions:   Drug: fezolinetant;   Drug: placebo
    Sponsor:   Astellas Pharma Global Development, Inc.
    Recruiting
  • A Double-blind Study to Assess 2 Doses of an Investigational Product for 16 Weeks in Participants With Non-alcoholic Fatty Liver Disease and Type 2 Diabetes Mellitus
    NCT03969719
    Condition:   Non-alcoholic Steatohepatitis
    Interventions:   Drug: Placebo;   Drug: PF-06835919
    Sponsor:   Pfizer
    Recruiting
  • A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate STS101 in the Acute Treatment of Migraine
    NCT03901482
    Conditions:   Migraine;   Migraine With Aura;   Migraine Without Aura
    Interventions:   Drug: Dihydroergotamine;   Drug: Placebos
    Sponsor:   Satsuma Pharmaceuticals, Inc.
    Recruiting
  • Immunotherapy With Nivolumab and Ipilimumab Followed by Nivolumab or Nivolumab With Cabozantinib for Patients With Advanced Kidney Cancer, The PDIGREE Study
    NCT03793166
    Conditions:   Clear Cell Renal Cell Carcinoma;   Metastatic Malignant Neoplasm in Lymph Node;   Metastatic Malignant Neoplasm in the Bone;   Metastatic Malignant Neoplasm in the Soft Tissues;   Metastatic Malignant Neoplasm in the Viscera;   Sarcomatoid Renal Cell Carcinoma;   Stage IV Renal Cell Cancer AJCC v8
    Interventions:   Drug: Cabozantinib;   Biological: Ipilimumab;   Biological: Nivolumab;   Other: Quality-of-Life Assessment;   Other: Questionnaire Administration
    Sponsor:   National Cancer Institute (NCI)
    Recruiting
  • An Active and Placebo-Controlled Study of Brazikumab in Participants With Moderately to Severely Active Ulcerative Colitis [EXPEDITION]
    NCT03616821
    Conditions:   Colitis;   Ulcerative;   IBD
    Interventions:   Drug: Brazikumab;   Drug: Vedolizumab;   Drug: Placebo
    Sponsor:   Allergan
    Recruiting
  • Study to Investigate CSL112 in Subjects With Acute Coronary Syndrome
    NCT03473223
    Condition:   Acute Coronary Syndrome
    Interventions:   Biological: Apolipoprotein A-I [human] (apoA-I);   Other: Placebo
    Sponsor:   CSL Behring
    Recruiting
  • AURORA: Phase 3 Study for the Efficacy and Safety of CVC for the Treatment of Liver Fibrosis in Adults With NASH
    NCT03028740
    Condition:   Nonalcoholic Steatohepatitis
    Interventions:   Drug: Cenicriviroc;   Drug: Placebo
    Sponsor:   Tobira Therapeutics, Inc.
    Recruiting
  • Study to Compare Oral PF-06651600, PF-06700841 and Placebo in Subjects With Moderate to Severe Ulcerative Colitis
    NCT02958865
    Condition:   Ulcerative Colitis
    Interventions:   Drug: PF-06651600 or Placebo;   Drug: PF-06700841 or Placebo;   Drug: PF-06700841;   Drug: PF-06651600
    Sponsor:   Pfizer
    Recruiting
  • Aspirin in Preventing Recurrence of Cancer in Patients With HER2 Negative Stage II-III Breast Cancer After Chemotherapy, Surgery, and/or Radiation Therapy
    NCT02927249
    Condition:   Node Positive HER2 Negative Breast Cancer
    Interventions:   Other: Placebo;   Drug: Aspirin
    Sponsors:   Alliance for Clinical Trials in Oncology;   National Cancer Institute (NCI);   United States Department of Defense;   Bayer;   Canadian Cancer Trials Group
    Recruiting
  • Direct Oral Anticoagulants (DOACs) Versus LMWH +/- Warfarin for VTE in Cancer
    NCT02744092
    Conditions:   Cancer;   Venous Thromboembolism;   Deep Vein Thrombosis (DVT);   Pulmonary Embolism (PE);   Blood Clot
    Interventions:   Drug: Rivaroxaban;   Drug: Apixaban;   Drug: Edoxaban;   Drug: Dabigatran;   Drug: Warfarin;   Drug: Dalteparin;   Drug: Enoxaparin;   Drug: Fondaparinux
    Sponsors:   Alliance Foundation Trials, LLC.;   Patient-Centered Outcomes Research Institute
    Recruiting
  • Doxorubicin Hydrochloride and Cyclophosphamide Followed by Paclitaxel With or Without Carboplatin in Treating Patients With Triple-Negative Breast Cancer
    NCT02488967
    Conditions:   Breast Adenocarcinoma;   Estrogen Receptor Negative;   HER2/Neu Negative;   Progesterone Receptor Negative;   Stage IB Breast Cancer;   Stage IIA Breast Cancer;   Stage IIB Breast Cancer;   Stage IIIA Breast Cancer;   Stage IIIC Breast Cancer;   Triple-Negative Breast Carcinoma
    Interventions:   Drug: Carboplatin;   Drug: Cyclophosphamide;   Drug: Doxorubicin Hydrochloride;   Other: Laboratory Biomarker Analysis;   Drug: Paclitaxel
    Sponsors:   NRG Oncology;   National Cancer Institute (NCI)
    Recruiting
  • Long Term, Extension Study of the Safety and Efficacy of AVP-786 for the Treatment of Agitation in Patients With Dementia of the Alzheimer's Type
    NCT02446132
    Condition:   Agitation in Patients With Dementia of the Alzheimer's Type
    Intervention:   Drug: AVP-786
    Sponsor:   Avanir Pharmaceuticals
    Recruiting
  • Genetic Testing in Screening Patients With Stage IB-IIIA Non-small Cell Lung Cancer That Has Been or Will Be Removed by Surgery (The ALCHEMIST Screening Trial)
    NCT02194738
    Conditions:   Lung Adenocarcinoma;   Lung Large Cell Carcinoma;   Resectable Lung Non-Small Cell Carcinoma;   Stage IB Lung Non-Small Cell Carcinoma AJCC v7;   Stage IB Lung Squamous Cell Carcinoma AJCC v7;   Stage II Lung Non-Small Cell Cancer AJCC v7;   Stage II Lung Squamous Cell Carcinoma AJCC v7;   Stage IIA Lung Non-Small Cell Carcinoma AJCC v7;   Stage IIA Lung Squamous Cell Carcinoma AJCC v7;   Stage IIB Lung Non-Small Cell Carcinoma AJCC v7;   Stage IIB Lung Squamous Cell Carcinoma AJCC v7;   Stage IIIA Lung Non-Small Cell Cancer AJCC v7;   Stage IIIA Lung Squamous Cell Carcinoma AJCC v7
    Interventions:   Other: Clinical Observation;   Drug: Crizotinib;   Other: Cytology Specimen Collection Procedure;   Drug: Erlotinib;   Drug: Erlotinib Hydrochloride;   Biological: Nivolumab;   Other: Placebo
    Sponsor:   National Cancer Institute (NCI)
    Recruiting
  • Erlotinib Hydrochloride in Treating Patients With Stage IB-IIIA Non-small Cell Lung Cancer That Has Been Completely Removed by Surgery (An ALCHEMIST Treatment Trial)
    NCT02193282
    Conditions:   EGFR Exon 19 Deletion Mutation;   EGFR NP_005219.2:p.L858R;   Stage IB Lung Non-Small Cell Carcinoma AJCC v7;   Stage II Lung Non-Small Cell Cancer AJCC v7;   Stage IIA Lung Non-Small Cell Carcinoma AJCC v7;   Stage IIB Lung Non-Small Cell Carcinoma AJCC v7;   Stage IIIA Lung Non-Small Cell Cancer AJCC v7
    Interventions:   Other: Clinical Observation;   Drug: Erlotinib;   Drug: Erlotinib Hydrochloride;   Other: Laboratory Biomarker Analysis;   Other: Placebo
    Sponsor:   National Cancer Institute (NCI)
    Recruiting
  • Active Surveillance, Bleomycin, Carboplatin, Etoposide, or Cisplatin in Treating Pediatric and Adult Patients With Germ Cell Tumors
    NCT03067181
    Conditions:   Childhood Extracranial Germ Cell Tumor;   Extragonadal Embryonal Carcinoma;   Germ Cell Tumor;   Malignant Germ Cell Tumor;   Malignant Ovarian Teratoma;   Stage I Ovarian Choriocarcinoma;   Stage I Ovarian Embryonal Carcinoma AJCC v6 and v7;   Stage I Ovarian Teratoma AJCC v6 and v7;   Stage I Ovarian Yolk Sac Tumor AJCC v6 and v7;   Stage I Testicular Choriocarcinoma AJCC v6 and v7;   Stage I Testicular Embryonal Carcinoma AJCC v6 and v7;   Stage I Testicular Yolk Sac Tumor AJCC v6 and v7;   Stage II Ovarian Choriocarcinoma;   Stage II Ovarian Embryonal Carcinoma AJCC v6 and v7;   Stage II Ovarian Yolk Sac Tumor AJCC v6 and v7;   Stage II Testicular Choriocarcinoma AJCC v6 and v7;   Stage II Testicular Embryonal Carcinoma AJCC v6 and v7;   Stage II Testicular Yolk Sac Tumor AJCC v6 and v7;   Stage III Ovarian Choriocarcinoma;   Stage III Ovarian Embryonal Carcinoma AJCC v6 and v7;   Stage III Ovarian Yolk Sac Tumor AJCC v6 and v7;   Stage III Testicular Choriocarcinoma AJCC v6 and v7;   Stage III Testicular Embryonal Carcinoma AJCC v6 and v7;   Stage III Testicular Yolk Sac Tumor AJCC v6 and v7;   Stage IV Ovarian Choriocarcinoma;   Stage IV Ovarian Embryonal Carcinoma AJCC v6 and v7;   Stage IV Ovarian Yolk Sac Tumor AJCC v6 and v7;   Testicular Mixed Choriocarcinoma and Embryonal Carcinoma;   Testicular Mixed Choriocarcinoma and Teratoma;   Testicular Mixed Choriocarcinoma and Yolk Sac Tumor
    Interventions:   Other: Best Practice;   Drug: Bleomycin;   Biological: Bleomycin Sulfate;   Drug: Carboplatin;   Drug: Cisplatin;   Drug: Etoposide;   Drug: Etoposide Phosphate;   Other: Laboratory Biomarker Analysis;   Other: Pharmacogenomic Study;   Other: Quality-of-Life Assessment;   Other: Questionnaire Administration
    Sponsors:   Children's Oncology Group;   National Cancer Institute (NCI)
    Recruiting
  • Combination Chemotherapy With or Without Temsirolimus in Treating Patients With Intermediate Risk Rhabdomyosarcoma
    NCT02567435
    Conditions:   Alveolar Rhabdomyosarcoma;   Botryoid-Type Embryonal Rhabdomyosarcoma;   Embryonal Rhabdomyosarcoma;   Rhabdomyosarcoma;   Sclerosing Rhabdomyosarcoma;   Spindle Cell Rhabdomyosarcoma
    Interventions:   Drug: Cyclophosphamide;   Biological: Dactinomycin;   Drug: Irinotecan Hydrochloride;   Other: Laboratory Biomarker Analysis;   Other: Questionnaire Administration;   Radiation: Radiation Therapy;   Drug: Temsirolimus;   Drug: Vincristine Sulfate;   Drug: Vinorelbine
    Sponsor:   National Cancer Institute (NCI)
    Recruiting
  • Psoriasis Longitudinal Assessment and Registry (PSOLAR)
    NCT00508547
    Conditions:   Psoriasis;   Arthritis, Psoriatic
    Interventions:   Biological: Ustekinumab;   Biological: Biological therapies other than infliximab, ustekinumab and guselkumab;   Drug: Conventional systemic agents;   Biological: Infliximab;   Biological: Guselkumab
    Sponsor:   Janssen Scientific Affairs, LLC
    Recruiting
  • Dysport in Vulvodynia Phase II Study
    NCT03598777
    Condition:   Vulvodynia
    Interventions:   Biological: Botulinum toxin type A;   Drug: Placebo
    Sponsor:   Ipsen
    Recruiting
  • A Phase Ib Study to Evaluate the Safety, Tolerability, and Pharmacokinetics (PK) of Avelumab in Combination With M9241(NHS-IL12) (JAVELIN IL-12)
    NCT02994953
    Condition:   Advanced Solid Tumors
    Interventions:   Drug: Avelumab;   Drug: M9241;   Drug: Avelumab (Once weekly);   Drug: M9241 (MTD);   Drug: Avelumab (Expansion cohort)
    Sponsors:   EMD Serono Research & Development Institute, Inc.;   Merck KGaA, Darmstadt, Germany
    Recruiting
  • A Study to Assess the Safety and Efficacy of ZPL389 in Patients With Moderate to Severe Atopic Dermatitis
    NCT03517566
    Condition:   Atopic Dermatitis
    Interventions:   Drug: Placebo;   Drug: ZPL389
    Sponsor:   Novartis Pharmaceuticals
    Recruiting
  • A Study of CG-806 in Patients With Relapsed or Refractory CLL/SLL or Non-Hodgkin's Lymphomas
    NCT03893682
    Conditions:   Chronic Lymphocytic Leukemia;   Small Lymphocytic Lymphoma;   Non-Hodgkin's Lymphoma
    Intervention:   Drug: CG-806
    Sponsor:   Aptose Biosciences Inc.
    Recruiting
  • M7824 Versus Pembrolizumab as a First-line (1L) Treatment in Participants With Programmed Death-ligand 1 (PD-L1) Expressing Advanced Non-small Cell Lung Cancer (NSCLC)
    NCT03631706
    Condition:   Non-small Cell Lung Cancer
    Interventions:   Drug: M7824;   Drug: Pembrolizumab
    Sponsors:   EMD Serono Research & Development Institute, Inc.;   Merck KGaA, Darmstadt, Germany
    Recruiting
  • A Study to Confirm Safety and Efficacy of BAN2401 in Participants With Early Alzheimer's Disease
    NCT03887455
    Condition:   Early Alzheimer's Disease
    Interventions:   Drug: BAN2401;   Drug: Placebo
    Sponsors:   Eisai Inc.;   Biogen
    Recruiting
  • A Study to Assess the Safety, Tolerability and Efficacy of Bimekizumab in Adult Subjects With Moderate to Severe Chronic Plaque Psoriasis
    NCT03598790
    Conditions:   Chronic Plaque Psoriasis;   Moderate to Severe Chronic Plaque Psoriasis
    Intervention:   Drug: Bimekizumab
    Sponsor:   UCB Biopharma S.P.R.L.
    Recruiting
  • A Study to Find Out if Fezolinetant Helps Reduce Moderate to Severe Hot Flashes in Women Going Through Menopause - 2
    NCT04003142
    Condition:   Hot Flashes
    Interventions:   Drug: fezolinetant;   Drug: placebo
    Sponsor:   Astellas Pharma Global Development, Inc.
    Recruiting
  • Ramucirumab and Pembrolizumab Versus Standard of Care in Treating Patients With Stage IV or Recurrent Non-small Cell Lung Cancer (A Lung-MAP Non-Match Treatment Trial)
    NCT03971474
    Conditions:   Recurrent Lung Non-Small Cell Carcinoma;   Stage IV Lung Cancer AJCC v8;   Stage IVA Lung Cancer AJCC v8;   Stage IVB Lung Cancer AJCC v8
    Interventions:   Drug: Docetaxel;   Drug: Gemcitabine;   Drug: Gemcitabine Hydrochloride;   Biological: Pembrolizumab;   Drug: Pemetrexed;   Drug: Pemetrexed Disodium;   Biological: Ramucirumab
    Sponsors:   Southwest Oncology Group;   National Cancer Institute (NCI)
    Recruiting
  • A Study to Evaluate Safety and Efficacy of PF-06826647 For Moderate To Severe Plaque Psoriasis
    NCT03895372
    Condition:   Psoriasis
    Interventions:   Drug: PF-06826647 or Placebo;   Drug: PF-06826647
    Sponsor:   Pfizer
    Recruiting
  • Lung-MAP: A Master Screening Protocol for Previously-Treated Non-Small Cell Lung Cancer
    NCT03851445
    Condition:   Previously Treated Non-Small Cell Lung Cancer
    Intervention:   Drug: Screening Platform
    Sponsors:   Southwest Oncology Group;   National Cancer Institute (NCI)
    Recruiting
  • Study to Evaluate the Efficacy and Safety of Vibegron Administered Orally for 12 Weeks to Women With Irritable Bowel Syndrome
    NCT03806127
    Condition:   Irritable Bowel Syndrome
    Interventions:   Drug: Vibegron;   Drug: Placebo
    Sponsor:   Urovant Sciences GmbH
    Recruiting
  • Firstline Pembrolizumab Alone or in Combination With Pemetrexed and Carboplatin in Induction/Maintenance or Postprogression in Treating Patients With Stage IV Non-squamous Non-small Cell Lung Cancer
    NCT03793179
    Conditions:   Lung Non-Squamous Non-Small Cell Carcinoma;   Stage IIIB Lung Cancer AJCC v8;   Stage IIIC Lung Cancer AJCC v8;   Stage IVA Lung Cancer AJCC v8
    Interventions:   Drug: Carboplatin;   Biological: Pembrolizumab;   Drug: Pemetrexed
    Sponsor:   National Cancer Institute (NCI)
    Recruiting
  • A Study of the Effect and Safety of Sparsentan in the Treatment of Patients With IgA Nephropathy
    NCT03762850
    Condition:   Immunoglobulin A Nephropathy
    Interventions:   Drug: sparsentan;   Drug: irbesartan
    Sponsor:   Retrophin, Inc.
    Recruiting
  • A Study to Assess Efficacy and Safety of SER‑287 in Adults With Active Mild-to-Moderate Ulcerative Colitis
    NCT03759041
    Condition:   Ulcerative Colitis
    Interventions:   Drug: Vancomycin Pre-Treatment;   Drug: Placebo for Vancomycin Pre-Treatment;   Drug: SER-287;   Drug: Placebo for SER-287
    Sponsor:   Seres Therapeutics, Inc.
    Recruiting
  • Biomarker/ALK Inhibitor Combinations in Treating Patients With Stage IV ALK Positive Non-squamous Non-small Cell Lung Cancer (The NCI-NRG ALK Protocol)
    NCT03737994
    Conditions:   Lung Non-Squamous Non-Small Cell Carcinoma;   Stage IV Lung Cancer AJCC v8;   Stage IVA Lung Cancer AJCC v8;   Stage IVB Lung Cancer AJCC v8
    Interventions:   Drug: Alectinib;   Drug: Brigatinib;   Drug: Carboplatin;   Drug: Ceritinib;   Drug: Cisplatin;   Drug: Crizotinib;   Drug: Ensartinib;   Drug: Lorlatinib;   Drug: Pemetrexed
    Sponsors:   National Cancer Institute (NCI);   NRG Oncology
    Recruiting
  • Serum Tumor Marker Directed Disease Monitoring in Patients With Hormone Receptor Positive Her2 Negative Metastatic Breast Cancer
    NCT03723928
    Conditions:   Anatomic Stage IV Breast Cancer AJCC v8;   Estrogen Receptor Positive;   HER2/Neu Negative;   Progesterone Receptor Positive;   Prognostic Stage IV Breast Cancer AJCC v8;   Elevated CA15-3 or CEA or CA27-29
    Interventions:   Other: Usual care disease monitoring;   Other: Serum Tumor Marker directed disease monitoring;   Other: Quality-of-Life Assessment;   Other: Anxiety Questionnaire Administration
    Sponsors:   Southwest Oncology Group;   National Cancer Institute (NCI)
    Recruiting
  • Ibrutinib and Obinutuzumab With or Without Venetoclax in Treating Patients With Chronic Lymphocytic Leukemia
    NCT03701282
    Conditions:   Chronic Lymphocytic Leukemia;   Small Lymphocytic Lymphoma
    Interventions:   Drug: Ibrutinib;   Biological: Obinutuzumab;   Other: Quality-of-Life Assessment;   Drug: Venetoclax
    Sponsor:   National Cancer Institute (NCI)
    Recruiting
  • Study to Assess the Long Term Safety and Tolerability of ACT-541468 in Adult and Elderly Subjects Suffering From Difficulties to Sleep
    NCT03679884
    Condition:   Insomnia Disorder
    Interventions:   Drug: ACT-541468 10 mg;   Drug: ACT-541468 25 mg;   Drug: ACT-541468 50 mg;   Drug: Placebo
    Sponsor:   Idorsia Pharmaceuticals Ltd.
    Recruiting
  • Evaluation of VISITAG SURPOINT™ Module With External Processing Unit (EPU)
    NCT03624881
    Condition:   Paroxysmal Atrial Fibrillation
    Intervention:   Device: Catheter ablation with EPU
    Sponsor:   Biosense Webster, Inc.
    Recruiting
  • Long-term Extension Trial in Subjects With Atopic Dermatitis Who Participated in Previous Tralokinumab Trials - ECZTEND
    NCT03587805
    Condition:   Atopic Dermatitis
    Intervention:   Drug: Tralokinumab
    Sponsor:   LEO Pharma
    Recruiting
  • A Cariprazine Study in the Prevention of Relapse in Bipolar I Disorder Patients Whose Current Episode is Manic or Depressive, With or Without Mixed Features
    NCT03573297
    Conditions:   Bipolar I Disorder;   Mania;   Depression
    Interventions:   Drug: Cariprazine;   Drug: Placebo
    Sponsor:   Forest Laboratories
    Recruiting
  • Study to Evaluate the Efficacy and Safety of Larazotide Acetate for the Relief of CeD Symptoms
    NCT03569007
    Condition:   Celiac Disease
    Interventions:   Drug: Larazotide;   Drug: Matching Placebo
    Sponsor:   Innovate Biopharmaceuticals
    Recruiting
  • A Trial of IW-3718 for 8 Weeks in Patients With Persistent Gastroesophageal Reflux Disease (GERD) Receiving Proton Pump Inhibitors
    NCT03561090
    Condition:   Gastroesophageal Reflux Disease (GERD)
    Interventions:   Drug: IW-3718;   Drug: placebo
    Sponsor:   Ironwood Pharmaceuticals, Inc.
    Recruiting
  • Study of Neratinib +Trastuzumab or Neratinib + Cetuximab in Patients With KRAS/NRAS/BRAF/PIK3CA Wild-Type Metastatic Colorectal Cancer by HER2 Status
    NCT03457896
    Condition:   Metastatic Colorectal Cancer
    Interventions:   Drug: Trastuzumab;   Drug: Cetuximab;   Drug: Neratinib;   Diagnostic Test: Guardant360 Diagnostic Test
    Sponsors:   NSABP Foundation Inc;   Puma Biotechnology, Inc.
    Recruiting
  • A Safety and Efficacy Study of Relamorelin in Diabetic Gastroparesis Study 04
    NCT03383146
    Conditions:   Gastroparesis;   Diabetes Mellitus
    Interventions:   Drug: Relamorelin;   Drug: Placebo
    Sponsor:   Allergan
    Recruiting
  • A Study of the Efficacy and Safety of Upadacitnib (ABT-494) in Subjects With Moderately to Severely Active Crohn's Disease Who Have Inadequately Responded to or Are Intolerant to Conventional and/or Biologic Therapies
    NCT03345849
    Condition:   Crohn's Disease
    Interventions:   Drug: Upadacitinib;   Drug: Placebo for Upadacitinib
    Sponsor:   AbbVie
    Recruiting
  • A Study of the Efficacy and Safety of Upadacitinib (ABT-494) in Subjects With Moderately to Severely Active Crohn's Disease Who Have Inadequately Responded to or Are Intolerant to Biologic Therapy
    NCT03345836
    Condition:   Crohn's Disease
    Interventions:   Other: Matching placebo for upadacitinib;   Drug: upadacitinib
    Sponsor:   AbbVie
    Recruiting
  • A Safety and Efficacy Study of Relamorelin in Diabetic Gastroparesis 01
    NCT03285308
    Conditions:   Gastroparesis;   Diabetes Mellitus
    Interventions:   Drug: Relamorelin;   Drug: Placebo
    Sponsor:   Allergan
    Recruiting
  • Clinical Trial of Neoadjuvant Chemotherapy With Atezolizumab or Placebo in Patients With Triple-Negative Breast Cancer Followed After Surgery by Atezolizumab or Placebo
    NCT03281954
    Condition:   Triple Negative Breast Cancer
    Interventions:   Drug: Placebo;   Drug: Atezolizumab
    Sponsors:   NSABP Foundation Inc;   Genentech, Inc.;   Hoffmann-La Roche
    Recruiting
  • Pembrolizumab in Treating Patients With Locally Advanced Bladder Cancer
    NCT03244384
    Conditions:   Stage II Bladder Urothelial Carcinoma AJCC v6 and v7;   Stage III Bladder Urothelial Carcinoma AJCC v6 and v7
    Interventions:   Other: Clinical Observation;   Other: Laboratory Biomarker Analysis;   Biological: Pembrolizumab;   Other: Pharmacological Study;   Other: Quality-of-Life Assessment;   Other: Questionnaire Administration
    Sponsor:   National Cancer Institute (NCI)
    Recruiting
  • Nivolumab After Combined Modality Therapy in Treating Patients With High Risk Stage II-IIIB Anal Cancer
    NCT03233711
    Conditions:   Anal Basaloid Carcinoma;   Anal Canal Cloacogenic Carcinoma;   Anal Margin Squamous Cell Carcinoma;   Stage IIB Anal Cancer AJCC v8;   Stage IIIA Anal Cancer AJCC v8;   Stage IIIB Anal Cancer AJCC v8;   Stage IIIC Anal Cancer AJCC v8
    Interventions:   Biological: Nivolumab;   Other: Patient Observation
    Sponsors:   National Cancer Institute (NCI);   Canadian Cancer Trials Group
    Recruiting
  • Extension Study of Pimavanserin for the Adjunctive Treatment of Schizophrenia
    NCT03121586
    Condition:   Schizophrenia
    Intervention:   Drug: Pimavanserin
    Sponsor:   ACADIA Pharmaceuticals Inc.
    Recruiting
  • MILD® Percutaneous Image-Guided Lumbar Decompression: A Medicare Claims Study
    NCT03072927
    Condition:   Lumbar Spinal Stenosis
    Intervention:   Device: MILD
    Sponsor:   Vertos Medical, Inc.
    Recruiting
  • Ipilimumab With or Without Nivolumab in Treating Patients With Melanoma That Is Stage IV or Stage III and Cannot Be Removed by Surgery
    NCT03033576
    Conditions:   Advanced Melanoma;   Melanoma of Unknown Primary;   Mucosal Melanoma;   Refractory Melanoma;   Stage III Cutaneous Melanoma AJCC v7;   Stage IIIA Cutaneous Melanoma AJCC v7;   Stage IIIB Cutaneous Melanoma AJCC v7;   Stage IIIC Cutaneous Melanoma AJCC v7;   Stage IV Cutaneous Melanoma AJCC v6 and v7;   Unresectable Cutaneous Melanoma;   Unresectable Melanoma
    Interventions:   Biological: Ipilimumab;   Biological: Nivolumab
    Sponsor:   National Cancer Institute (NCI)
    Recruiting
  • Combination Chemotherapy, Bevacizumab, and/or Atezolizumab in Treating Patients With Deficient DNA Mismatch Repair Metastatic Colorectal Cancer
    NCT02997228
    Conditions:   Colorectal Adenocarcinoma;   Stage IV Colorectal Cancer AJCC v7;   Stage IVA Colorectal Cancer AJCC v7;   Stage IVB Colorectal Cancer AJCC v7
    Interventions:   Drug: Atezolizumab;   Biological: Bevacizumab;   Drug: Fluorouracil;   Drug: Leucovorin Calcium;   Drug: Oxaliplatin;   Other: Quality-of-Life Assessment;   Other: Questionnaire Administration
    Sponsors:   National Cancer Institute (NCI);   NRG Oncology
    Recruiting
  • Pembrolizumab in Treating Patients With Triple-Negative Breast Cancer
    NCT02954874
    Conditions:   Invasive Breast Carcinoma;   Stage 0 Breast Cancer AJCC v6 and v7;   Stage I Breast Cancer AJCC v7;   Stage IA Breast Cancer AJCC v7;   Stage IB Breast Cancer AJCC v7;   Stage II Breast Cancer AJCC v6 and v7;   Stage IIA Breast Cancer AJCC v6 and v7;   Stage IIB Breast Cancer AJCC v6 and v7;   Stage III Breast Cancer AJCC v7;   Stage IIIA Breast Cancer AJCC v7;   Stage IIIB Breast Cancer AJCC v7;   Stage IIIC Breast Cancer AJCC v7;   Triple-Negative Breast Carcinoma
    Interventions:   Other: Laboratory Biomarker Analysis;   Other: Patient Observation;   Biological: Pembrolizumab;   Other: Quality-of-Life Assessment;   Other: Questionnaire Administration;   Radiation: Radiation Therapy
    Sponsor:   National Cancer Institute (NCI)
    Recruiting
  • A Study Comparing the Efficacy and Safety of Etrolizumab With Adalimumab and Placebo in Participants With Moderate to Severe Ulcerative Colitis (UC) in Participants Naive to Tumor Necrosis Factor (TNF) Inhibitors (Study #1)
    NCT02163759
    Condition:   Ulcerative Colitis
    Interventions:   Drug: Adalimumab;   Other: Adalimumab Placebo;   Drug: Etrolizumab;   Other: Etrolizumab Placebo
    Sponsor:   Hoffmann-La Roche
    Recruiting
  • Combination Chemotherapy With or Without Atezolizumab in Treating Patients With Stage III Colon Cancer and Deficient DNA Mismatch Repair
    NCT02912559
    Conditions:   Colon Adenocarcinoma;   DNA Repair Disorder;   Lynch Syndrome;   Stage III Colon Cancer AJCC v7;   Stage IIIA Colon Cancer AJCC v7;   Stage IIIB Colon Cancer AJCC v7;   Stage IIIC Colon Cancer AJCC v7
    Interventions:   Drug: Atezolizumab;   Drug: Fluorouracil;   Other: Laboratory Biomarker Analysis;   Drug: Leucovorin Calcium;   Drug: Oxaliplatin;   Other: Quality-of-Life Assessment
    Sponsor:   National Cancer Institute (NCI)
    Recruiting
  • Anemia Studies in Chronic Kidney Disease: Erythropoiesis Via a Novel Prolyl Hydroxylase Inhibitor Daprodustat-Non-Dialysis (ASCEND-ND)
    NCT02876835
    Condition:   Anaemia
    Interventions:   Drug: Daprodustat;   Drug: Darbepoetin alfa;   Drug: Placebo;   Drug: Iron Therapy
    Sponsor:   GlaxoSmithKline
    Recruiting
  • Study of Safety and Efficacy of Tropifexor (LJN452) in Patients With Non-alcoholic Steatohepatitis (NASH)
    NCT02855164
    Condition:   Non-alcoholic Steatohepatitis (NASH)
    Interventions:   Drug: Tropifexor (LJN452);   Drug: Placebo
    Sponsor:   Novartis Pharmaceuticals
    Recruiting
  • A Long-term Safety Study of Esketamine Nasal Spray in Treatment-resistant Depression
    NCT02782104
    Condition:   Depressive Disorder, Treatment-Resistant
    Intervention:   Drug: Esketamine Nasal Spray
    Sponsor:   Janssen Research & Development, LLC
    Recruiting
  • A Study of CAD106 and CNP520 Versus Placebo in Participants at Risk for the Onset of Clinical Symptoms of Alzheimer's Disease
    NCT02565511
    Condition:   Alzheimer's Disease
    Interventions:   Biological: CAD106 Immunotherapy;   Other: Placebo to CAD106;   Drug: CNP520;   Other: Placebo to CNP520
    Sponsors:   Novartis Pharmaceuticals;   Banner Alzheimer's Institute;   National Institute on Aging (NIA);   Alzheimer's Association;   Amgen
    Recruiting
  • A Study Of Avelumab In Combination With Other Cancer Immunotherapies In Advanced Malignancies (JAVELIN Medley)
    NCT02554812
    Condition:   Advanced Cancer
    Interventions:   Drug: Avelumab;   Drug: Utomilumab;   Drug: PF-04518600;   Drug: PD 0360324;   Drug: CMP-001
    Sponsor:   Pfizer
    Recruiting
  • Dabrafenib and Trametinib Followed by Ipilimumab and Nivolumab or Ipilimumab and Nivolumab Followed by Dabrafenib and Trametinib in Treating Patients With Stage III-IV BRAFV600 Melanoma
    NCT02224781
    Conditions:   Metastatic Melanoma;   Recurrent Melanoma;   Stage III Cutaneous Melanoma AJCC v7;   Stage IIIA Cutaneous Melanoma AJCC v7;   Stage IIIB Cutaneous Melanoma AJCC v7;   Stage IIIC Cutaneous Melanoma AJCC v7;   Stage IV Cutaneous Melanoma AJCC v6 and v7;   Unresectable Cutaneous Melanoma
    Interventions:   Drug: Dabrafenib;   Drug: Dabrafenib Mesylate;   Biological: Ipilimumab;   Biological: Nivolumab;   Other: Quality-of-Life Assessment;   Drug: Trametinib;   Drug: Trametinib Dimethyl Sulfoxide
    Sponsor:   National Cancer Institute (NCI)
    Recruiting
  • A Study to Determine the Outcomes of Patients With Localized B Cell Lymphoblastic Lymphoma (B-LLy) When Treated With Standard Risk B-ALL Therapy
    NCT03914625
    Conditions:   B Acute Lymphoblastic Leukemia;   B Lymphoblastic Lymphoma;   Down Syndrome
    Interventions:   Drug: Asparaginase Erwinia chrysanthemi;   Biological: Blinatumomab;   Drug: Cyclophosphamide;   Drug: Cytarabine;   Drug: Dexamethasone;   Drug: Doxorubicin;   Drug: Doxorubicin Hydrochloride;   Drug: Leucovorin;   Drug: Leucovorin Calcium;   Drug: Mercaptopurine;   Drug: Mercaptopurine Oral Suspension;   Drug: Methotrexate;   Drug: Prednisolone;   Drug: Prednisone;   Drug: Thioguanine;   Drug: Vincristine;   Drug: Vincristine Sulfate
    Sponsor:   National Cancer Institute (NCI)
    Recruiting
  • A Long-Term Registry of Humira® (Adalimumab) in Patients With Moderately to Severely Active Ulcerative Colitis (UC)
    NCT01848561
    Condition:   Ulcerative Colitis (UC)
    Intervention:  
    Sponsor:   AbbVie
    Recruiting
  • Cancer Care Delivery in Adolescent and Young Adult Patients With Acute Lymphoblastic Leukemia
    NCT03204916
    Condition:   Acute Lymphoblastic Leukemia
    Interventions:   Other: Medical Chart Review;   Other: Questionnaire Administration
    Sponsors:   Children's Oncology Group;   National Cancer Institute (NCI)
    Recruiting
  • Targeted Therapy Directed by Genetic Testing in Treating Pediatric Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphomas, or Histiocytic Disorders (The Pediatric MATCH Screening Trial)
    NCT03155620
    Conditions:   Advanced Malignant Solid Neoplasm;   Ann Arbor Stage III Non-Hodgkin Lymphoma;   Ann Arbor Stage IV Non-Hodgkin Lymphoma;   Histiocytic Sarcoma;   Juvenile Xanthogranuloma;   Langerhans Cell Histiocytosis;   Malignant Glioma;   Recurrent Central Nervous System Neoplasm;   Recurrent Childhood Rhabdomyosarcoma;   Recurrent Ependymoma;   Recurrent Ewing Sarcoma;   Recurrent Glioma;   Recurrent Hepatoblastoma;   Recurrent Langerhans Cell Histiocytosis;   Recurrent Malignant Germ Cell Tumor;   Recurrent Malignant Solid Neoplasm;   Recurrent Medulloblastoma;   Recurrent Neuroblastoma;   Recurrent Non-Hodgkin Lymphoma;   Recurrent Osteosarcoma;   Recurrent Peripheral Primitive Neuroectodermal Tumor;   Recurrent Rhabdoid Tumor;   Recurrent Soft Tissue Sarcoma;   Refractory Central Nervous System Neoplasm;   Refractory Ewing Sarcoma;   Refractory Glioma;   Refractory Hepatoblastoma;   Refractory Langerhans Cell Histiocytosis;   Refractory Malignant Germ Cell Tumor;   Refractory Malignant Solid Neoplasm;   Refractory Medulloblastoma;   Refractory Neuroblastoma;   Refractory Non-Hodgkin Lymphoma;   Refractory Osteosarcoma;   Refractory Peripheral Primitive Neuroectodermal Tumor;   Refractory Rhabdoid Tumor;   Refractory Rhabdomyosarcoma;   Rhabdoid Tumor;   Stage III Osteosarcoma AJCC v7;   Stage III Soft Tissue Sarcoma AJCC v7;   Stage IV Osteosarcoma AJCC v7;   Stage IV Soft Tissue Sarcoma AJCC v7;   Stage IVA Osteosarcoma AJCC v7;   Stage IVB Osteosarcoma AJCC v7;   Wilms Tumor
    Interventions:   Procedure: Biopsy;   Procedure: Biospecimen Collection;   Drug: Ensartinib;   Drug: Erdafitinib;   Other: Laboratory Biomarker Analysis;   Drug: Larotrectinib;   Procedure: Mutation Carrier Screening;   Drug: Olaparib;   Drug: Palbociclib;   Other: Pharmacological Study;   Drug: Samotolisib;   Drug: Selumetinib Sulfate;   Drug: Tazemetostat;   Drug: Ulixertinib;   Drug: Vemurafenib
    Sponsor:   National Cancer Institute (NCI)
    Recruiting
  • Cabozantinib-S-Malate in Treating Younger Patients With Recurrent, Refractory, or Newly Diagnosed Sarcomas, Wilms Tumor, or Other Rare Tumors
    NCT02867592
    Conditions:   Adrenal Cortex Carcinoma;   Alveolar Soft Part Sarcoma;   Central Nervous System Neoplasm;   Childhood Clear Cell Sarcoma of Soft Parts;   Clear Cell Sarcoma of Soft Tissue;   Ewing Sarcoma;   Hepatoblastoma;   Hepatocellular Carcinoma;   Osteosarcoma;   Recurrent Adrenal Cortex Carcinoma;   Recurrent Alveolar Soft Part Sarcoma;   Recurrent Ewing Sarcoma;   Recurrent Hepatoblastoma;   Recurrent Hepatocellular Carcinoma;   Recurrent Malignant Central Nervous System Neoplasm;   Recurrent Malignant Solid Neoplasm;   Recurrent Osteosarcoma;   Recurrent Renal Cell Carcinoma;   Recurrent Rhabdomyosarcoma;   Recurrent Soft Tissue Sarcoma;   Recurrent Thyroid Gland Medullary Carcinoma;   Refractory Ewing Sarcoma;   Refractory Malignant Central Nervous System Neoplasm;   Refractory Malignant Solid Neoplasm;   Refractory Osteosarcoma;   Refractory Rhabdomyosarcoma;   Refractory Soft Tissue Sarcoma;   Renal Cell Carcinoma;   Rhabdomyosarcoma;   Solid Neoplasm;   Thyroid Gland Medullary Carcinoma;   Wilms Tumor
    Interventions:   Drug: Cabozantinib;   Drug: Cabozantinib S-malate;   Other: Pharmacological Study
    Sponsor:   National Cancer Institute (NCI)
    Recruiting
  • A Phase 2 Study of Ruxolitinib With Chemotherapy in Children With Acute Lymphoblastic Leukemia
    NCT02723994
    Condition:   Leukemia
    Interventions:   Drug: Ruxolitinib;   Drug: Asparaginase Erwinia Chrysanthemi;   Drug: Cyclophosphamide;   Drug: Cytarabine;   Drug: Dexamethasone;   Drug: Doxorubicin;   Drug: Leucovorin Calcium;   Drug: Mercaptopurine;   Drug: Methotrexate;   Drug: Pegaspargase;   Drug: Prednisone;   Drug: Thioguanine;   Drug: Vincristine Sulfate
    Sponsors:   Incyte Corporation;   Children's Oncology Group
    Recruiting
  • S0820, Adenoma and Second Primary Prevention Trial
    NCT01349881
    Condition:   Colorectal Neoplasms
    Interventions:   Drug: Eflornithine placebo & sulindac placebo;   Drug: eflornithine & sulindac placebo;   Drug: Eflornithine placebo & sulindac;   Drug: Eflornithine plus sulindac
    Sponsors:   Southwest Oncology Group;   National Cancer Institute (NCI);   Cancer Prevention Pharmaceuticals, Inc.
    Recruiting
  • Multi-center Study to Validate niPGT-A
    NCT03520933
    Conditions:   Aneuploidy;   Chromosome Abnormality;   Infertility
    Interventions:   Diagnostic Test: PGT-A;   Diagnostic Test: niPGT-A
    Sponsor:   Igenomix
    Recruiting
  • Comparison of MENOPUR Liquid and Powder in Women Undergoing ART
    NCT04163458
    Condition:   Infertility
    Interventions:   Drug: MENOPUR solution for injection in pre-filled pen, 1200 IU/1.92 mL;   Drug: MENOPUR powder and solvent for solution for injection, 75 IU;   Other: Placebo (for MENOPUR solution for injection in pre-filled pen);   Other: Placebo (for MENOPUR powder and solvent for solution for injection)
    Sponsor:   Ferring Pharmaceuticals
    Recruiting
  • Safety, Tolerability and Efficacy Study of V117957 in Subjects With Insomnia Associated With Alcohol Cessation
    NCT04035200
    Condition:   Insomnia
    Interventions:   Drug: V117957 tablets;   Drug: Placebo
    Sponsor:   Imbrium Therapeutics
    Recruiting
  • The Safety and Efficacy of Psilocybin in Participants With Treatment Resistant Depression
    NCT03775200
    Condition:   Treatment Resistant Depression
    Intervention:   Drug: Psilocybin
    Sponsor:   COMPASS Pathways
    Recruiting
  • A Study of ABI-H2158 in Healthy Volunteers and Patients With Chronic Hepatitis B
    NCT03714152
    Condition:   Chronic Hepatitis B
    Interventions:   Drug: ABI-H2158;   Drug: Placebo for ABI-H2158
    Sponsor:   Assembly Biosciences
    Recruiting
  • Medical Optimization of Management of Type 2 Diabetes Complicating Pregnancy (MOMPOD)
    NCT02932475
    Conditions:   Diabetes;   Pregnancy
    Interventions:   Drug: Metformin;   Drug: Placebo
    Sponsors:   University of North Carolina, Chapel Hill;   Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
    Recruiting
  • Study of a Levonorgestrel 52 mg Intrauterine System for the Treatment of Heavy Menstrual Bleeding
    NCT03642210
    Condition:   Menorrhagia
    Intervention:   Combination Product: Levonorgestrel 52 mg intrauterine system
    Sponsor:   Medicines360
    Recruiting
  • Pregnancy Outcome and Safety of Interrupting Therapy for Women With Endocrine Responsive Breast Cancer
    NCT02308085
    Condition:   Early Breast Cancer
    Intervention:   Other: Endocrine therapy interruption
    Sponsors:   International Breast Cancer Study Group;   Alliance for Clinical Trials in Oncology;   Canadian Cancer Trials Group;   Breast International Group
    Recruiting
  • Short-term Clinical Deterioration After Acute Pulmonary Embolism
    NCT03915925
    Condition:   Pulmonary Embolism
    Intervention:  
    Sponsors:   Atrium Health;   Agency for Healthcare Research and Quality (AHRQ)
    Recruiting
  • A Study to Evaluate the Safety, Tolerability, and Efficacy of SAGE-217 Compared to Placebo in Adult Subjects With Comorbid Major Depressive Disorder and Insomnia
    NCT03771664
    Conditions:   Major Depressive Disorder;   Insomnia
    Interventions:   Drug: SAGE-217;   Drug: Placebo
    Sponsor:   Sage Therapeutics
    Recruiting
  • Longitudinal Performance of Epi proColon
    NCT03218423
    Conditions:   Colorectal Cancer;   Colorectal Neoplasms
    Intervention:   Device: Epi proColon
    Sponsor:   Epigenomics, Inc
    Recruiting
  • A Study to Assess the Effects of RO6889450 in Participants With Schizophrenia or Schizoaffective Disorder and Negative Symptoms
    NCT03669640
    Condition:   Schizophrenia, Schizoaffective Disorder
    Interventions:   Drug: RO6889450;   Drug: Placebo
    Sponsor:   Hoffmann-La Roche
    Recruiting
  • A Study to Evaluate the Efficacy and Safety of Gefapixant (MK-7264) in Women With Endometriosis-Related Pain (MK-7264-034)
    NCT03654326
    Condition:   Endometriosis-related Pain
    Interventions:   Drug: Gefapixant;   Drug: Placebo;   Drug: Naproxen
    Sponsor:   Merck Sharp & Dohme Corp.
    Recruiting
  • Traditional Versus Early Aggressive Therapy for Multiple Sclerosis Trial
    NCT03500328
    Condition:   Multiple Sclerosis, Relapsing-Remitting
    Intervention:   Other: Early Aggressive Therapy or Traditional Therapy
    Sponsors:   Johns Hopkins University;   Patient-Centered Outcomes Research Institute
    Recruiting
  • Efficacy, Safety, and Tolerability of AVP-786 for the Treatment of Negative Symptoms of Schizophrenia
    NCT03896945
    Condition:   Schizophrenia
    Interventions:   Drug: Placebo;   Drug: AVP-786
    Sponsor:   Avanir Pharmaceuticals
    Recruiting
  • A Study to Evaluate Efficacy, Safety, Tolerability, and Pharmacokinetics of 3 Dose Levels of TAK-831 in Adjunctive Treatment of Adult Participants With Negative Symptoms of Schizophrenia
    NCT03382639
    Condition:   Schizophrenia
    Interventions:   Drug: TAK-831;   Drug: Placebo
    Sponsor:   Millennium Pharmaceuticals, Inc.
    Recruiting

Popular Now

  • Privacy Policy
  • Ad and Cookie Policy
  • Infringement Policy
  • Terms of Use
  • Email Policy
  • Contact Us
  • Post Clinical Trials
  • Join Clinical Trials
  • Volunteer Login
  • Recruiters Login
  • Frequently Asked Questions
  • Blog
  • Find Clinical Trials
  • Find Volunteers
  • Trials by Category
  • Trials by Location
  • Volunteers by Category
  • Volunteers by Location
All clinical trials are registered and certified with clinicaltrials.gov. Data via U.S. National Library of Medicine,U.S. National Institutes of Health, U.S. Department of Health & Human Services. JoinClinicaltrials.com (Aunica Media llc) is a free resource that provides individuals and companies with information regarding clinical trials that are being conducted nationwide. Aunica Media llc does not conduct clinical trials nor endorses them. Please consult your doctor or physician before participating. And Ye shall know the truth, and the truth shall make you free
©2001-2019 Aunica Media LLC